GlassScriptPhysician profile
Martin D Harvey
NPI 1043223639
$4,817.23
in general payments reported to CMS, 2019-2025
30 companies · $628 in 2025
The $628 reported for 2025 was more than what 78% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $753 · 2020: $801 · 2021: $527 · 2022: $433 · 2023: $714 · 2024: $962 · 2025: $628.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,304.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,303.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,008.97 | 2019-2025 | Farxiga, Airsupra, Lokelma |
| Novo Nordisk INC | $639.41 | 2019-2025 | Ozempic, Rybelsus |
| Pfizer INC. | $485.78 | 2019-2025 | |
| Lilly USA, LLC | $408.53 | 2020-2024 | Mounjaro, Jardiance, Zepbound |
| Abbvie INC. | $358.21 | 2020-2025 | |
| Merck Sharp & Dohme LLC | $309.54 | 2019-2023 | Verquvo, Belsomra, Steglatro |
| Astellas Pharma US INC | $211.43 | 2019-2023 | Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $182.70 | 2020-2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $113.14 | 2025 | Caplyta |
| Phathom Pharmaceuticals, INC. | $93.98 | 2024 | Voquezna |
| Glaxosmithkline, LLC. | $92.34 | 2019-2024 | Trelegy Ellipta |
| Abbott Laboratories | $88.40 | 2022-2025 | Freestyle Libre 3, Diamondback Coronary |
| Lexicon Pharmaceuticals, INC. | $86.26 | 2023-2024 | Inpefa |
| Takeda Pharmaceuticals U.S.A., INC. | $80.90 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $65.46 | 2023-2024 | Nuedexta, Rexulti |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $64.30 | 2019-2023 | Repatha |
| Novartis Pharmaceuticals Corporation | $62.54 | 2019-2023 | |
| Allergan, INC. | $58.87 | 2020 | |
| Shield Therapeutics INC | $56.67 | 2023-2024 | Accrufer |
| E.R. Squibb & Sons, L.L.C. | $55.42 | 2019-2021 | |
| Ibsa Pharma INC. | $52.34 | 2023-2024 | Licart, Tirosint, Tirosint |
| Medtronic, INC. | $39.56 | 2022-2025 | Intellis Adaptivestim |
| Bayer Healthcare Pharmaceuticals INC. | $35.11 | 2022-2024 | |
| Esperion Therapeutics, INC. | $35.08 | 2024-2025 | Nexletol |
| Lundbeck LLC | $35.05 | 2024 | Vyepti |
| Janssen Pharmaceuticals, INC | $29.62 | 2019-2020 | |
| Amarin Pharma, INC. | $18.37 | 2019 | |
| Corium, LLC | $17.77 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $15.77 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $15.71 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Martin Harvey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.